Home - Products - Others - Other Targets - 16 alpha-Hydroxytrametenolic acid

16 alpha-Hydroxytrametenolic acid

CAS No. 176390-68-4

16 alpha-Hydroxytrametenolic acid( —— )

Catalog No. M31443 CAS No. 176390-68-4

16 alpha-Hydroxytrametenolic acid can inhibit 12-O-tetradecanoylphorbol 13-acetate (TAP)-induced mouse ear edema.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 421 In Stock
10MG 603 In Stock
50MG Get Quote In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    16 alpha-Hydroxytrametenolic acid
  • Note
    Research use only, not for human use.
  • Brief Description
    16 alpha-Hydroxytrametenolic acid can inhibit 12-O-tetradecanoylphorbol 13-acetate (TAP)-induced mouse ear edema.
  • Description
    16 alpha-Hydroxytrametenolic acid can inhibit 12-O-tetradecanoylphorbol 13-acetate (TAP)-induced mouse ear edema.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    176390-68-4
  • Formula Weight
    472.7
  • Molecular Formula
    C30H48O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • GW-870086

    GW-870086 is an effective anti-inflammatory agent. GW-870086 also plays a role in a glucocorticoid receptor agonist (pIC50: 10.1 in A549 cells expressing NF-κB).

  • Taltirelin acetate

    Taltirelin acetate is a superagonist at thyrotropin-releasing hormone receptor (TRH-R)(IC50 of 910 nM and EC50 of 36 nM for stimulating an increase in cytosolic Ca2+ concentration (Ca2+ release)).

  • Disitamab vedotin

    Disitamab vedotin (RC-48) is a newly developed antibody-active molecule conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), consisting of hertuzumab coupled to monomethyl auristatin E (MMAE) via a cleavable linker.